<p>The effects of (A) gefitinib and (B) erlotinib (1–10 μM) on cell proliferation of A549 cells were investigated. Cell counts were estimated by the MTT assay. Data are expressed as means ± S.E.M. of three independent experiments. Each symbol indicates significant differences from DMSO group; a, <i>p</i> < 0.05; aa, <i>p</i> < 0.01 (DMSO vs. 1 μM), bb, <i>p</i> < 0.01; bbb, <i>p</i> < 0.001 (DMSO vs. 5 μM), c, <i>p</i> < 0.05; cc, <i>p</i> < 0.01; ccc, <i>p</i> < 0.001 (DMSO vs. 10 μM), one-way ANOVA with Dunnett’s post hoc tests.</p
<p>Cell proliferation in AG1478 (left), gefitinib (middle) and erlotinib (right) was measured by SRB...
<p>The effects of gefitinib and erlotinib (10 μM) on (A) eIF2α/ATF4 activation and (C) PERK migratio...
Total EGFR and total ERK are also shown for comparison. β-actin western blots and Coomassie blue sta...
Cells were incubated with vehicle, ., non-stimulated, or increasing concentration of gefitinib for 2...
<p>A549 cells were treated with gefitinib (10 μM), erlotinib (10 μM) or tunicamycin (2.5 μg/mL) for ...
<p>(<b>A</b>) OSC19 cells were treated with the indicated concentrations of erlotinib, a small molec...
<p>Panel A indicates the net directional invasive movement (A – B; as defined in Fig. 1) of pII cell...
<p>(A) LN229, U251 and HS683 cells were left untreated or were treated for 24 h with erlotinib and s...
<p>(<b>A</b>), Treatment of SCC1 and OSC19 cells with GSPs decreases the overexpression of EGFR and ...
<p>(<b>A</b>) Treatment of OSC19 cells with GSPs decreases the basal levels of NF-κB/p65 and IKKα wh...
<p>The concentration-response response for each drug was used to determine the concentration that in...
<p><i><sup>*</sup>P</i><0.05 when compared with the model group, <sup>Δ</sup><i>P</i><0.05 when comp...
<p>Growth was monitored by MTT assays. Cells were treated with gefitinib 5 µM and DIM-C 3 µM and com...
<p>A, HCC4006ER cells were treated for 72 hours with increasing concentrations of indicated reagents...
<p>(A) MTS assay comparing the survival curves of control JLO-1 to 2 µM gefitinib-treated JLO-1 when...
<p>Cell proliferation in AG1478 (left), gefitinib (middle) and erlotinib (right) was measured by SRB...
<p>The effects of gefitinib and erlotinib (10 μM) on (A) eIF2α/ATF4 activation and (C) PERK migratio...
Total EGFR and total ERK are also shown for comparison. β-actin western blots and Coomassie blue sta...
Cells were incubated with vehicle, ., non-stimulated, or increasing concentration of gefitinib for 2...
<p>A549 cells were treated with gefitinib (10 μM), erlotinib (10 μM) or tunicamycin (2.5 μg/mL) for ...
<p>(<b>A</b>) OSC19 cells were treated with the indicated concentrations of erlotinib, a small molec...
<p>Panel A indicates the net directional invasive movement (A – B; as defined in Fig. 1) of pII cell...
<p>(A) LN229, U251 and HS683 cells were left untreated or were treated for 24 h with erlotinib and s...
<p>(<b>A</b>), Treatment of SCC1 and OSC19 cells with GSPs decreases the overexpression of EGFR and ...
<p>(<b>A</b>) Treatment of OSC19 cells with GSPs decreases the basal levels of NF-κB/p65 and IKKα wh...
<p>The concentration-response response for each drug was used to determine the concentration that in...
<p><i><sup>*</sup>P</i><0.05 when compared with the model group, <sup>Δ</sup><i>P</i><0.05 when comp...
<p>Growth was monitored by MTT assays. Cells were treated with gefitinib 5 µM and DIM-C 3 µM and com...
<p>A, HCC4006ER cells were treated for 72 hours with increasing concentrations of indicated reagents...
<p>(A) MTS assay comparing the survival curves of control JLO-1 to 2 µM gefitinib-treated JLO-1 when...
<p>Cell proliferation in AG1478 (left), gefitinib (middle) and erlotinib (right) was measured by SRB...
<p>The effects of gefitinib and erlotinib (10 μM) on (A) eIF2α/ATF4 activation and (C) PERK migratio...
Total EGFR and total ERK are also shown for comparison. β-actin western blots and Coomassie blue sta...